potency of pd-1 and ctla -4 bispecific or combination in humanized mouse model dr. richard stebbings
Published 1 year ago • 212 plays • Length 17:41Download video MP4
Download video MP3
Similar videos
-
1:54
two main pathways involved in immunotherapy pd 1 and ctla4
-
7:37
combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
-
16:51
jax live! bispecific antibody testing using pbmc humanized mice
-
1:23
pd-1 immunotherapy explained in under 2 minutes!
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
6:13
anti-pd-1 or anti-ctla-4 in first line therapy?
-
9:02
pd1/ ctla4 : upfront or sequentially?
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
4:32
pd-1 and ox40: potential pdac combination therapy
-
1:49
functions of pd-l1 in tumor extracellular vesicles and implications for cancer therapy
-
11:40
toxicities associated with anti–pd-1 immunotherapy
-
1:23
exploring the combination anti-ctla-4 and anti-pd-1 in multiple myeloma post-transplant
-
1:48
the role of pd l1 in the immune dysfunction that mediates hypoxia induced multiple organ injury
-
2:50
the evolution of pd-l1 immunotherapy for bladder cancer
-
0:45
the what, why, and how of anti-pd-1/pd-l1 immunotherapy for cancer
-
1:24
kd033, a pdl1-1l15 bispecific molecule for the treatment of cancer
-
1:25
pd-1 and pd-l1 expression in esophageal and gastric cancer
-
4:15
pathologists and pd-l1
-
1:49
pd-1 inhibitor clinical trials (conditions a-z)